Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Multiple myeloma Stories

2013-05-21 08:29:21

STOCKHOLM, May 21, 2013 /PRNewswire/ -- Oncopeptides AB, a company working to enhance oncology therapies, today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management and Board also participated in the round. (Logo: http://photos.prnewswire.com/prnh/20130521/613959 ) The investment will finance a phase...

2013-05-15 20:23:38

Enrollment in Phase 1 Clinical Trials of ABT-199 in Chronic Lymphocytic Leukemia Continues NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago. Data being presented include the results from two clinical trials evaluating the safety and...

2013-05-01 12:28:45

Second Janssen oncology compound to receive Breakthrough Therapy Designation RARITAN, N.J., May 1, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double...

2013-04-04 08:28:50

BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Results on the...

2013-04-02 10:47:08

Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites...

2013-02-11 08:26:18

NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Senesco Technologies, Inc. (OTC: SNTI) announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > red "register/ watch event now" button Senesco's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks. About Senesco Technologies, Inc. Senesco...

2013-02-06 10:59:33

New research in animals triggered by a combination of serendipity and counterintuitive thinking could point the way to treating fractures caused by rapid bone loss in people, including patients with metastatic cancers. A series of studies at the University of North Carolina School of Medicine found that steroid drugs, known for inducing bone loss with prolonged use, actually help suppress a molecule that's key to the rapid bone loss process. A report of the new findings appears online Feb....

2013-01-25 10:23:12

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.  This phase I clinical trial enrolled 38 patients, and pomalidomide provided a minimal or better response for 42 percent of the patients, a partial response or better for 21 percent, and a complete response for 3 percent....

2012-12-20 08:27:18

BALTIMORE, Dec. 20, 2012 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced that researchers from University of Pennsylvania and University of Maryland presented at the American Society of Hematology (ASH) Annual Meeting interim clinical data from a study that included treatment of high-risk multiple myeloma patients with Gliknik's MAGE-A3 immunomodulator, GL-0817. GL-0817 is in ongoing Phase II clinical studies in both multiple myeloma and head and...

2012-12-13 06:20:04

This discovery may potentially cure patients of multiple myelomaSingapore, Dec 13, 2012 - (ACN Newswire) - Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow. Patients with this form of cancer usually do not get cured with current standard treatments such as chemotherapy and stem cell transplantation, with an average survival of only about four years. FAIM could thus be a...